109782 ⎘
dsDNA viruses; Details; Herpesviridae; Cytomegalovirus, e.g. human herpesvirus 5 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
PREFUSION-STABILIZED CMV GB PROTEINS
#2PRE-FUSION-STABILIZED CMV GB PROTEIN NANOSTRUCTURES
#3MODIFIED VIRUS-LIKE PARTICLES OF CMV
#4Use of Triplex CMV Vaccine in CAR T Cell Therapy
#5MODIFIED T CELLS AND METHODS OF THEIR USE
#6IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME
#7CELL MEDIATED IMMUNE RESPONSE ASSAY
#8CYTOMEGALOVIRUS T CELL EPITOPES AND USES THEREOF
#9GENE-DRIVE IN DNA VIRUSES
#10DUAL FUNCTION ANTIGEN BINDING MOLECULES
#11Human Cytomegalovirus Immunogenic Composition
#12ANTIGEN DELIVERY PLATFORMS
#13METHODS FOR PRODUCING CMV VECTORS
#14IMMUNOGENIC COMPOSITIONS AND USES THEREOF
#15ENGINEERED FC DOMAINS AND ENGINEERED HCMV VIRAL FC RECEPTORS
#16CHIMERIC POLYPEPTIDE COMPOSITIONS AND ENCODING POLYNUCLEOTIDES THEREOF
#17MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS
#18HUMAN CYTOMEGALOVIRUS RNA VACCINES
#19T-Cell Engaging Polypeptides and Methods of Use Thereof
#20MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
#21T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof
#22PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF VIRAL ANTIGENS AND RELATED METHODS
#23Use of Triplex CMV Vaccine in CAR T Cell Therapy
#24CMV VECTORS AND USES THEREOF
#25MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#26MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS
#27MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES
#28A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY
#29METHODS AND VACCINES FOR INDUCING IMMUNE RESPONSES TO MULTIPLE DIFFERENT MHC MOLECULES
#30Compositions, methods and kits for eliciting an immune response
#31T CELL EPITOPES OF HCMV AND USES OF THEREOF
#32HEPATITIS B VIRUS VACCINES
#33COMPOSITIONS AND METHODS FOR DETECTING HIV LATENCY, TREATING HIV INFECTION, AND REVERSING HIV LATENCY
#34Antigen delivery platforms
#35COMPLEXES OF CYTOMEGALOVIRUS PROTEINS
#36Recombinant viral vector, immune composition containing same, and use thereof
#37Adoptive T-Cell Therapy for CMV Infection and CMV-Associated Diseases
#38Human herpesvirus immunotherapy
#39Potent and short promoter for expression of heterologous genes
#40Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
#41Universal T cells and the method of use thereof
#42HCMV vaccine strain
#43Viral particle-based vaccine
#44GENE-DRIVE IN DNA VIRUSES
#45Potent and balanced bidirectional promoter
#46MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#47MODIFIED T CELLS AND METHODS OF THEIR USE
#48CMV VECTORS AND USES THEREOF
#49Use of Triplex CMV Vaccine in CAR T Cell Therapy
#50HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
#51Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
#52Compositions, methods and kits for eliciting an immune response
#53Compositions, methods and kits for eliciting an immune response
#54IMPROVED T CELL COMPOSITIONS AND METHODS
#55IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME
#56T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
#57Compositions, methods and kits for eliciting an immune response
#58Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#59Human cytomegalovirus RNA vaccines
#60Compositions, methods and kits for eliciting an immune response
#61Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
#62Cell mediated immune response assay
#63MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#64IL-12 IMMUNOTHERAPY FOR CANCER
#65Human cytomegalovirus neutralizing antibodies and use thereof
#66EXPRESSION VECTORS COMPRISING CHIMERIC CYTOMEGALOVIRUS PROMOTER AND ENHANCER SEQUENCES
#67MITOCHONDRIAL DELIVERY OF RECOMBINANT NUCLEIC ACIDS
#68CMV PROMOTER AND METHOD FOR PRODUCTION OF POLYPEPTIDES
#69Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#70Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
#71Human cytomegalovirus RNA vaccines
#72Potent and balanced bidirectional promoter
#73Potent and balanced bidirectional promoter
#74Antigen delivery platforms
#75Human cytomegalovirus gB polypeptide
#76Hybrid promoter and uses thereof
#77Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells
#78Methods and vaccines for inducing immune responses to multiple different MHC molecules
#79Human cytomegalovirus neutralizing antibodies and use thereof
#80MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#81Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
#82Human cytomegalovirus RNA vaccines
#83Cytomegalovirus antigens
#84Potent and short promoter for expression of heterologous genes
#85Human herpesvirus immunotherapy
#86Compositions, methods and kits for eliciting an immune response
#87NOVEL CMV PP65 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
#88Human cytomegalovirus neutralizing antibodies and use thereof
#89Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
#90CMV ANTIGENS AND USES THEREOF
#91Cytomegalovirus antigens and uses thereof
#92Mammalian cells expressing cytomegalovirus antigens
#93Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
#94Human cytomegalovirus neutralizing antibodies and use thereof
#95Complexes of cytomegalovirus proteins
#96Human cytomegalovirus neutralizing antibodies and use thereof
#97Human cytomegalovirus neutralizing antibodies and use thereof
#98HUMAN CYTOMEGALOVIRUS VACCINE COMPOSITIONS AND METHOD OF PRODUCING THE SAME
#99CMV promoter and method for production of polypeptides
#100Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
#101Human cytomegalovirus neutralizing antibodies and use thereof
#102Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia
#103Complexes of cytomegalovirus proteins
#104Human cytomegalovirus neutralizing antibodies and use thereof
#105IL-12 immunotherapy for cancer
#106Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
#107Human cytomegalovirus neutralizing antibodies and use thereof
#108Compositions and methods of use thereof for identifying anti-viral agents
#109Human cytomegalovirus neutralizing antibodies and use thereof
#110Compositions, methods, and kits for eliciting an immune response
#111Cell mediated immune response assay
#112Human herpesvirus immunotherapy
#113EXPRESSION VECTORS COMPRISING THE MCMV IE2 PROMOTER
#114Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
#115MVA vaccine for delivery of a UL128 complex and preventing CMV infection
#116Peptide compositions and methods for inhibiting herpesvirus infection
#117Human cytomegalovirus neutralizing antibodies and use thereof
#118Human cytomegalovirus neutralizing antibodies and use thereof
#119Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#120Genetic variant of cytomegalovirus (CMV)
#121Methods and compositions for cytomegalovirus IL-10 protein
#122Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
#123Peptide scaffold design
#124Human cytomegalovirus neutralizing antibodies and use thereof
#125Expression vector and methods of producing high levels of proteins
#126Compositions, methods, and kits for eliciting an immune response
#127Human cytomegalovirus neutralizing antibodies and use thereof
#128Codon-optimized polynucleotide-based vaccines against human infection
#129Peptide compositions and methods for inhibiting herpesvirus infection
#130Compositions, methods, and kits for eliciting an immune response
#131Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#132Promote system for regulatable gene expression in mammalian cells
#133Human cytomegalovirus neutralizing antibodies and use thereof
#134Human cytomegalovirus neutralizing antibodies and use thereof
#135CYTOMEGALOVIRUS INTRON A FRAGMENTS
#136IMMUNOGENIC COMPOSITION COMPRISING PEPTIDES DERIVED FROM CYTOMEGALOVIRUS AND THE USE THEREOF
#137Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
#138Human cytomegalovirus neutralizing antibodies and use thereof
#139Fusion Protein Delivery System and Uses Thereof
#140Expression vector and methods of producing high levels of proteins
#141Combinatorial analysis and repair
#142Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#143Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#144VARIANT HCMV PP65, IE1, AND IE2 POLYNUCLEOTIDES AND USES THEREOF
#145VIRAL NUCLEIC ACID FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#146Cytomegalovirus disintegrin-like peptides
#147Expression vectors comprising the mCMV IE2 promoter
#148IL-12 immunotherapy for cancer
#149PLASMID CONTAINING A SEQUENCE ENCODING A DISINTEGRIN DOMAIN OF METARGIDIN (RDD)
#150Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
#151TRANSGENIC ONCOLYTIC VIRUSES AND USES THEREOF
#152Human Cytomegalovirus Latency Promoting Genes, Related Virus Variants and Methods of Use
#153CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF
#154Human cytomegalovirus neutralizing antibodies and use thereof
#155RECOMBINANT ANTIGENS OF HUMAN CYTOMEGALOVIRUS (HCMV)
#156PROTEIN KINASE DEFICIENT, IMMUNOLOGICALLY ACTIVE CMVpp65 MUTANT CELLULAR VACCINES
#157Method of elicting or inducing an immune response
#158Therapeutic anti-cytomegalovirus compounds
#159DNA EXPRESSION VECTORS
#160Promoter
#161METHOD FOR ISOLATING HEPATITIS C VIRUS PEPTIDES
#162Detection of primary infections with pathogens
#163Fusion protein delivery system and uses thereof
#164Methods and Compositions for Detecting Target Sequences
#165CELLULAR IMMUNITY TEST WITH PEPTIDES ATTACHED TO A SOLID SUPPORT
#166Cytomegalovirus surface protein complex for use in vaccines and as a drug target
#167Methods and Compositions for Detecting Target Sequences
#168Cytomegalovirus vaccine
#169Human cytomegalovirus immunotherapy
#170Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
#171Expression vectors comprising the mCMV IE2 promoter
#172Thermoreversible oil-in-water emulsion
#173Human cytomegalovirus DNA sequences
#174Vectors comprising guinea pig CMV regulatory elements
#175Method for isolating hepatitis C virus peptides
#176Peptides for vaccination against human CMV
#177Cellular immunity test with peptides fixed on a solid support
#178Protein kinase deficient, immunologically active CMVpp65 mutants
#179Cytomegalovirus disintegrin-like peptides
#180Method for isolating ligands
#181Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
#182Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
#183ASSAY FOR SCREENING FOR AN ANTI-VIRAL AGENT
#184Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors
#185Alpha virus-based cytomegalovirus vaccines
#186Diagnostic reagents for human cytomegalovirus and methods of use
#187Human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
#188Fusion protein delivery system and uses thereof